Pathology of triple negative breast cancer
F Borri, A Granaglia - Seminars in cancer biology, 2021 - Elsevier
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …
Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies
GK Gupta, AL Collier, D Lee, RA Hoefer, V Zheleva… - Cancers, 2020 - mdpi.com
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN) …
Background In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …
[HTML][HTML] Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
A Santonja, A Sánchez-Muñoz, A Lluch… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular
subtypes that differentially respond to chemotherapy and targeted agents. The purpose of …
subtypes that differentially respond to chemotherapy and targeted agents. The purpose of …
Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review
A Szymiczek, A Lone, MR Akbari - Clinical genetics, 2021 - Wiley Online Library
Breast cancer is a heterogeneous disease manifesting diversity at the molecular,
histological and clinical level. The development of breast cancer classification was centered …
histological and clinical level. The development of breast cancer classification was centered …
CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence
Y Zhao, Z Pan, S Namburi, A Pattison, A Posner… - …, 2020 - thelancet.com
Background Cancer of unknown primary (CUP), representing approximately 3-5% of all
malignancies, is defined as metastatic cancer where a primary site of origin cannot be found …
malignancies, is defined as metastatic cancer where a primary site of origin cannot be found …
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity
could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based …
could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based …
Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective …
The HER2-positive patients occupy~ 30% of the total breast cancer patients globally where
no prevalent drugs are available to mitigate the frequent metastasis clinically except …
no prevalent drugs are available to mitigate the frequent metastasis clinically except …
Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine
F Derouane, C van Marcke, M Berlière, A Gerday… - Cancers, 2022 - mdpi.com
Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …
setting of breast cancer, there is a clinical need for predictive markers of response in daily …